Wilms' tumour is a paediatric malignancy of the kidneys that affects one in every 10 000 live births, making it the most common solid tumour in the young. This cancer arises due to a failure of the metanephric mesenchyme to differentiate and form the kidney filtration units and tubules, which instead undergo uncontrolled proliferation. WT1 (Wilms' tumour 1) was identified as a factor that is frequently mutated in Wilms' tumours. WT1 plays a central role in the development of the genito-urinary organs and also other regions of the embryo. A major function of WT1 is to act as a regulator of transcription, controlling the expression of genes that are involved in proliferation and differentiation. WT1 can either activate or repress transcription of its target genes. Thus the transcription function of WT1 is highly context-specific, and can be modulated by a number of cofactors. Here, the known interaction partners of WT1 and the mechanisms by which they modulate WT1 transcription function will be discussed.
Introduction
Wilms' tumour is a paediatric malignancy of the kidneys that affects 1 in 10 000 children (reviewed in [1, 2] ). The tumour arises from abnormal development of the kidneys that leads to increased cellular proliferation instead of differentiation. The Wilms' tumour suppressor protein WT1 (Wilms' tumour 1) was identified on the basis of its frequent mutation in Wilms' tumours. However, WT1 mutations are present in only 10-15% of Wilms' tumours, and while some also show elevated expression of WT1, it is clear that other factors can also contribute to Wilms tumorigenesis. WT1 null mice die in utero, displaying complete agenesis of the kidneys and also several other organs, including gonad, spleen and adrenal glands [3, 4] . Thus WT1 is a critical regulator of the development of the genito-urinary system and other organs. In addition, areas of the nervous system, including the retinal ganglia and olfactory epithelium, fail to develop in WT1 knockout mice [5, 6] . The mice die, however, due to defects in heart development that most probably arise from a requirement for WT1 in the formation of the mesothelium that lines the internal organs [3] .
The initial analysis of the primary structure of WT1 revealed the presence of the four zinc fingers similar to those found in the transcription factor Egr1 ( Figure 1 ) [7] . The N-terminus of WT1 contains a proline-rich region that is typical of transcriptional regulators. It was thus proposed that WT1 might be a transcription factor, and subsequent transient transfection experiments demonstrated that WT1 was able to repress transcription at reporter constructs containing the promoters of several genes, including those encoding insulin-like growth factor II and platelet-derived growth factor A [8] [9] [10] . These gene products, among others, are elevated in Wilms' tumours, and the finding that WT1 could repress their transcription provided a working hypothesis for how loss of WT1 function might lead to Wilms' tumorigenesis.
WT1 is subject to alternative splicing at two sites ( Figure 1) . One of the alternative forms of WT1 contains an additional three amino acids (lysine, threonine, serine; KTS) between zinc fingers 3 and 4. This alternative splice form is conserved in WT1 from all species for which sequence information is available [11] . The other alternative splice site inserts an additional 17 amino acids at the C-terminus of the transcriptional regulatory region and is found only in mammalian WT1 (17aa form). The number of potential WT1 isoforms is increased further by both upstream and downstream alternative translation events (reviewed in [1] ). Moreover, RNA editing of WT1 has been reported that results in either leucine or proline at position 280 [12] . Finally, a recent report has described an alternative promoter of the WT1 gene that resides within the first intron [13] . This promoter results in the generation of a novel, smaller form of WT1 that lacks the N-terminal transcriptional repression region. This alternative promoter is paternally imprinted, a property that appears to be lost in some Wilms' tumours.
Analysis of the +KTS and −KTS forms of WT1 suggests that they may have different functions in gene expression. Although both forms of WT1 can bind to both DNA and RNA, the −KTS form shows a preference for the former and the +KTS form for the latter (for review see [1] ). In addition, immunofluorescence studies have demonstrated that the +KTS and −KTS forms associate with different regions of the nucleus [14] . WT1 −KTS associates with transcription factors within the nucleus, while WT1 +KTS associates with coiled bodies and splicing factors [15, 16] .
Mice have been generated that express exclusively either the +KTS or the −KTS form of WT1 ( [17] ; reviewed in [18] ). Unlike the completely WT1 null mice, both the +KTS and −KTS mice survive to birth. This suggests that there is functional overlap between the two isoforms. Indeed, both mice show development of the adrenal glands and spleen, suggesting that the +KTS and −KTS forms can perform the same functions in these organs. However, in the gonads and kidney, neither the +KTS or the −KTS form of WT1 was able to provide complete function by itself. Thus mice that lack the +KTS form of WT1 develop as females even when they are XY status. On the other hand, although both the +KTS and −KTS forms of WT1 are required for complete development of the kidney, the −KTS form plays a more important role, and its ablation causes a severe reduction in nephrogenesis.
Mice expressing a truncated form of WT1 that lacks nucleic-acid-binding activity have also been generated [19] [20] [21] . These mice mimic the effects of WT1 mutations found in the human condition DDS (Denys Drash syndrome), which is typified by gonad abnormalities, nephropathy and a high incidence of Wilms' tumour. Because WT1 self-associates via its N-terminus, it is believed that these forms of WT1, through heterodimerization, act as dominant negative inhibitors of wild-type WT1 [22] [23] [24] . The 'Denys Drash mice' exhibit genito-urinary abnormalities similar to those observed in human DDS patients.
In addition to the above, mice have been generated that lack the 17aa isoform of WT1 [25] . These mice do not exhibit any defects in genito-urinary development or reproduction. However, mice that express truncated forms of WT1 (the DDS mutations described above) show differences when the truncated WT1 contains the 17 amino acids [21] . Thus, although the 17-amino-acid insert does not appear to be critical in mouse development, its presence can exert an effect in a defective WT1 background. Mice have also been generated that are unable to produce WT1 that is derived from the upstream translation event [26] . Again, these mice do not show any obvious defects in development of the genito-urinary system. Thus it is possible that the 17aa and N-terminally extended forms of WT1 have redundant functions, or that they are not needed in mouse development. 
Transcriptional regulation by WT1
As stated above, WT1 was initially characterized as a transcriptional regulator, and specifically as a repressor of transcription. However, further work suggested that this may not be the full story. The ability of WT1 to repress transcription was highly dependent on the cell line that was used and also the precise promoter construct that was employed (reviewed in [1] ). In addition, the transcription effects mediated by WT1 were dependent upon the vector that was used to drive WT1 expression. At this time, reports were emerging that WT1 could activate transcription at some promoters (e.g. syndecan 1 [27] and p21 [28] ). DNA microarray analyses were in agreement with this notion, finding that amphiregulin and podocalyxin were targets of WT1, and that the effect mediated was transcriptional activation [29, 30] . Amphiregulin is a growth factor of the epidermal growth factor family and is expressed in the kidneys during nephrogenesis. In the kidney, podocalyxin is expressed specifically in the podocytes, where it is important for the elaborate morphology of these cells, which form a crucial part of the filtration barrier. Indeed, WT1 expression is restricted to the podocytes of the adult kidney, where it is required to maintain their differentiated state. More recently, nephrin, another gene product that is critical in podocyte morphology, was described as a target gene that is [31, 32] . The gene encoding the anti-apoptotic factor Bcl-2 has also been reported as a target of WT1 [33] . Several labs have reported the effects of WT1 on apoptosis (reviewed in [1] ). Significantly, Bcl-2 knockout mice show defects in kidney development typified by a significant decrease in the number of nephrons.
It is now clear that transcriptional regulation by WT1 is highly context-dependent. The prevailing view is that the disparate effects of WT1 are mediated by factors that associate with WT1 (Figure 2) . Indeed, gel filtration chromatography studies suggest that WT1 is contained within large complexes [34] . Thus the last few years have seen a major effort to identify interaction partners for WT1. These WT1-binding proteins may provide clues to the cell-type-and promoter-dependent activities of WT1. Here I will discuss our current understanding of the function of the WT1 interaction partners. This will be restricted to the WT1 interaction partners that have been implicated in the transcription function of WT1. However, it is important to appreciate that, as transcription and RNA processing are integrated activities, WT1-binding proteins that have been proposed to play a role in RNA processing may well ultimately be found to affect transcriptional regulation by WT1.
DNA-binding proteins that interact with WT1
The p53 family WT1 has been found to interact with members of the p53 family. In baby rat kidney cells, WT1 and p53 co-immunoprecipitate, and WT1 can stabilize p53 and thereby enhance DNA binding by p53 and transcriptional activation [35] . The interaction involves the zinc finger region of WT1. p53 can also augment transcriptional repression by WT1 in reporter assays. Analysis of p53/WT1 compound transgenic mice adds further weight to the notion of a functional interplay between p53 and WT1 [36] . WT1/p53 null mouse embryos reach a later stage in gestation before resorption than WT1 null mice. However, the underlying physiological mechanisms that are involved remain to be determined. WT1 can also interact with p73 via its zinc fingers [37] . This interaction modulates DNA binding by WT1, and reduces transcriptional activation mediated by both WT1 and p73.
Cholesterol biosynthesis pathway
A microarray screen was used to find genes that are regulated following the ablation of WT1 expression in M15 cells using an antisense approach [38] . In addition, a microarray was performed following ectopic expression of WT1 in HEK 293 cells. A common finding using both approaches was a cluster of genes involved in cholesterol biosynthesis that were found to be repressed by WT1. The transcription of these genes is normally activated by SREBPs (sterol responsive element-binding proteins), which bind to their promoter regions. WT1 can interact directly with SREBP, and it was suggested that WT1 acts as a 
WT1 partners in the gonad
The WT1 −KTS isoform can interact with SF-1 (steroidogenic factor-1) [39] . Together, they synergistically activate the MIS (Mullerian inhibiting substance) promoter. WT1 mutations that result in male pseudohermaphroditism are unable to co-operate with SF-1, suggesting a molecular basis for the WT1-associated syndromes that result in gonadal defects. Dax-1 can antagonize the co-operative transcriptional activation mediated by WT1/SF-1 by binding to SF-1. Interestingly, the co-activator FHL2 (four-and-a-half LIM domain protein) interacts with WT1 and potentiates WT1-mediated transcriptional activation of the Dax-1 promoter [40] . FHL2 and WT1 are co-expressed in developing testes and ovary. It was proposed that, during differentiation of the ovary, WT1 and FHL2 co-operate to activate the Dax-1 gene, which in turn causes repression of the MIS gene. Thus WT1, SF-1 and Dax-1 integrate to form a molecular switch in gonad differentiation.
'Classical' transcription targets of WT1
The transcriptional activation region of WT1 resides within residues 180-250 [41] . As yet we know very little about how the WT1 transcriptional activation domain functions. A glutathione S-transferase fusion protein containing the WT1 activation domain can bind to the general transcription factor TFIIB, which is an interaction partner for many activation domains [42] . However, there are no functional data regarding the mechanism of action of the WT1 transcriptional activation domain.
WT1 has been demonstrated to interact with the co-activators CBP [CREB (cAMP response element-binding protein)-binding protein] and p300 [43] . These interactions enhance transcriptional activation by WT1. CBP interacts with the zinc finger DNA-binding region of WT1. The zinc finger region of WT1 is not in itself a transcriptional activation domain, but it is possible that it co-operates with the transcriptional activation domain in the context of the intact protein.
It has been reported that WT1 can interact with the adenovirus E1b 55 kDa protein [44] . This interaction also occurs via the zinc fingers. The interaction with E1b 55K sequesters WT1 along with p53 into cytoplasmic bodies. Although it is not clear how this regulates gene expression, E1b 55K is able to abrogate WT1-mediated induction of apoptosis.
Non DNA-binding proteins
WT1 has been shown to interact with a number of proteins that do not directly contact DNA, but are implicated in transcription through known pathways or via protein sequence motifs. Immunoprecipitation of WT1 from cell extracts identified Hsp70 (heat-shock protein 70) as a WT1-interacting protein [45] . Hsp70 interacts with the N-terminus of WT1, a region known to be involved in WT1 self-association. It was also found that expression of WT1 leads to transactivation of the Hsp70 promoter. The promoter element responsible for this effect is the HSE (heat shock element). A model is proposed in which WT1 binds to Hsp70 via its N-terminus, and in so doing releases HSF (heat-shock factor) from Hsp70, which then transactivates the Hsp70 promoter. Hsp70 does not appear to affect transcriptional regulation mediated by WT1.
BMZF2 (bone marrow zinc finger 2) was isolated as a WT1-interacting protein by affinity chromatography using a column containing the WT1 zinc fingers [46] . BMZF2 inhibits transcriptional activation mediated by WT1 in reporter assays. BMZF2 is expressed primarily in the embryo, where expression is observed in the developing kidney. In addition, as its name suggests, BMZF2 is expressed in the haematopoietic lineage, in which WT1 is also present.
Ciao1 was isolated in a yeast two-hybrid screen to identify factors that interact with the full-length WT1 −KTS isoform [47] . Ciao1 contains seven WD40 repeats, a motif known to be involved in the formation of protein complexes. The zinc finger region of WT1 appears to be involved in the interaction with Ciao1. In transfection assays Ciao1 inhibits WT1-mediated transcriptional activation at a synthetic reporter.
Par-4 (prostate apoptosis response-4)
WT1 has also been shown to interact with several proteins that have not previously been associated with gene regulation. One of these, Par-4, is a protein that is involved in apoptosis. Par-4 was isolated as a WT1-interacting protein in a yeast two-hybrid screen using intact WT1 as bait [48] . Par-4 was shown to augment transcriptional repression by WT1, which was mediated by a direct interaction with the WT1 zinc fingers. It has become apparent that Par-4 can contact a second region in WT1 that is formed by the insertion of the extra 17 amino acids by alternative splicing [49] . In this context, the region encompassing the 17 amino acids forms a second transcriptional activation domain in WT1 that is dependent upon Par-4 as a transcriptional co-activator. Thus Par-4 can act as either a transcriptional co-activator or as a co-repressor for WT1, and this is dependent upon the splice isoform of WT1. The interaction of the 17aa isoform of WT1 with Par-4 appears to confer a cell-survival function and is able to rescue cells from UV-mediated apoptosis [49] .
WTIP (WT1-interacting protein)
A yeast two-hybrid screen using the WT1 −KTS isoform as bait isolated a novel LIM-domain-containing protein, WTIP [50] . WTIP is co-expressed with WT1 in the forming glomeruli of the developing kidney, and was also expressed in a podocyte cell line. In the latter case WTIP was localized to the cytoplasm. However, inhibition of the CRM1 (chromosome region maintenance 1) nuclear export pathway results in nuclear accumulation of WTIP and subsequent interaction with WT1. This leads to inhibition of transcriptional activation by WT1. These results suggested a context-dependent function for the WT1-WTIP interaction. Treatment of cultured podocytes with puromycin aminonucleoside causes disruption of cell-cell contacts and retraction of the podocyte foot processes. This leads to nuclear translocation of WTIP and association with WT1 [51] . Thus it is possible that the WT1-WTIP association is regulated by damage to the podocytes, and that this then elicits a changed programme of gene expression. This scenario is in agreement with the notion that WT1 is needed in the podocyte cells to help maintain their differentiated state.
BASP1 (brain acid-soluble protein 1)
Using an in vitro transcription assay, we functionally identified a WT1 transcriptional co-suppressor protein [52] . The N-terminus of WT1 contains a region (suppression domain) that inhibits the transcriptional activation domain (see Figure 1 ). This suppression domain is a potent inhibitor of transcriptional activation in vitro at a synthetic reporter. Using a functional transcription assay system to monitor WT1 transcriptional co-suppressor activity, BASP1 was identified as an interaction partner for the WT1 suppression domain. BASP1 is expressed in the developing nephrons of the embryonic kidney and, like WT1, becomes restricted to the podocyte cells of the adult kidney. BASP1 elicits WT1-dependent transcriptional co-suppressor activity in transient transfection assays. In addition, ablation of BASP1 expression using siRNA (small interfering RNA) leads to transcriptional activation of the amphiregulin gene by WT1.
Modulation of WT1 transcription function
Our understanding of WT1 function so far suggests that a large number of factors can modulate its activities. This raises the question of how these different interactions are integrated into a coherent functional outcome (Figure 3) . What are the circumstances under which these different interactions with WT1 occur? This could be achieved by regulation of the expression of the WT1 cofactor. For example, Par-4 levels are elevated in response to pro-apoptotic conditions. Also, the WT1-WTIP interaction is modulated by translocation of WTIP to the nucleus following damage to podocytes. In both of these cases, the interaction of WT1 with the cofactor is context-specific, either by modulation of the level of the cofactor or by relocalization of the cofactor.
It is also possible that the ability of WT1 to interact with its cofactors is regulated by direct modification of WT1 itself. For example, WT1 has recently been shown to be sumoylated [53] , and this may modulate its ability to interact with target factors. Phosphorylation of WT1 [54] might also regulate the ability of WT1 to interact with other proteins. In addition, WT1 has been shown to undergo nucleocytoplasmic shuttling, which could affect its availability to interact with other factors [55, 56] . Some of the interactions with WT1 have been found to be WT1-isoform-specific. In addition, the subnuclear localization of WT1 shows isoform specificity. These properties of WT1 are likely to lead to the modulation of WT1 interaction events, with resulting changes in WT1-mediated transcriptional events. Future studies will focus on how WT1-associated proteins modify WT1 function in development and disease. 
